Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
Authors
Keywords
Overall Survival, Soft Tissue Sarcoma, Partial Remission, Leiomyosarcoma, Liposarcoma
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-01-19
DOI
10.1186/s12885-016-2054-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trabectedin and its potential in the treatment of soft tissue sarcoma
- (2016) J Fayette Therapeutics and Clinical Risk Management
- Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group
- (2015) Axel Le Cesne et al. EUROPEAN JOURNAL OF CANCER
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) ANNALS OF ONCOLOGY
- Trabectedin for advanced soft tissue sarcomas: a single institution experience
- (2014) Ioannis Gounaris et al. Future Oncology
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study
- (2013) B. L. Samuels et al. ANNALS OF ONCOLOGY
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
- (2013) Jean-Yves Blay et al. BMC CANCER
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
- (2012) Axel Le Cesne et al. INVESTIGATIONAL NEW DRUGS
- Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
- (2010) G. Germano et al. CANCER RESEARCH
- Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
- (2010) Thomas Schmitt et al. Marine Drugs
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution
- (2009) Jérôme Fayette et al. ANTI-CANCER DRUGS
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
- (2009) Stefan Sleijfer et al. EUROPEAN JOURNAL OF CANCER
- Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study
- (2009) D.S. McMeekin et al. GYNECOLOGIC ONCOLOGY
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
- (2009) C. Forni et al. MOLECULAR CANCER THERAPEUTICS
- Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
- (2009) Carmen Cuevas et al. NATURAL PRODUCT REPORTS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity
- (2007) Jin Kyung Lee et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More